NCT01110083View on ClinicalTrials.gov

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

March 31, 2012

Conditions
Solid Tumors
Interventions
DRUG

EMD 1204831

Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle

Trial Locations (1)

Unknown

M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT01110083 - First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter